Back to today’s briefing

Story perspectives

AI Revolutionizes Pharma: UK and China Lead Innovation

6/11/2025

24 5

Summary

Story summary

The pharmaceutical landscape is evolving as AI and drug delivery innovations reshape outsourcing models. The UK government is backing AI-driven drug discovery with the OpenBind consortium, while China fosters global collaboration through significant pharmaceutical events. Meanwhile, Juvenescence's acquisition of Ro5 underscores a commitment to enhancing AI in drug development, signaling a bold shift towards innovation in the industry.

History

Historical Context

The FDA's 2012 approval of the first AI-developed drug marked a significant shift in pharmaceutical innovation, addressing the over 50% failure rate of new drugs in trials. This trend continues today, with initiatives like the UK's OpenBind consortium and advancements in China, highlighting the increasing reliance on AI technologies to enhance drug discovery efficiency and collaboration in the industry.

1 of 2

Story summary

The pharmaceutical landscape is evolving as AI and drug delivery innovations reshape outsourcing models. The UK government is backing AI-driven drug discovery with the OpenBind consortium, while China fosters global collaboration through significant pharmaceutical events. Meanwhile, Juvenescence's acquisition of Ro5 underscores a commitment to enhancing AI in drug development, signaling a bold shift towards innovation in the industry.

1 / 2